Clinical Application of Non-invasive PGT-A

Sponsor
Kaohsiung Veterans General Hospital. (Other)
Overall Status
Recruiting
CT.gov ID
NCT04856696
Collaborator
Sofiva Genomics Co., Ltd. (Industry)
120
1
3
27.2
4.4

Study Details

Study Description

Brief Summary

The study aims to investigate the difference of in vitro fertilization (IVF) outcomes among non-invasive PGT-A, PGT-A and combined non-invasive PGT-A and PGT-A.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: PGT-A
  • Diagnostic Test: non-invasive PGT-A
N/A

Detailed Description

Background Chromosome abnormality is a leading cause of implantation failure and miscarriage. Chromosome abnormality increases with age, resulting in reduced pregnancy rate. Nowadays, preimplantation genetic testing for aneuploidies (PGT-A) could be used for detection of aneuploidy. However, PGT-A needs embryo biopsy which is invasive and may cause embryo damage. It was found that cell free DNA could be isolated from culture media. The cell free DNA from culture media also could be used to detect embryo ploidy, called non-invasive PGT-A.

Objective The study aims to investigate the difference of in vitro fertilization (IVF) outcomes among non-invasive PGT-A, PGT-A and combined non-invasive PGT-A and PGT-A. Another aim of this study is to check the concordance rate between non-invasive PGT-A and PGT-A.

Methods The prospective cohort study will be performed at the reproductive medical center of Kaohsiung Veterans General Hospital, in Kaohsiung, Taiwan. Participants who plan to receive an IVF cycle and preimplantation genetic testing for aneuploidies will be enrolled in this study. The investigators will divide the participants into 3 groups: (1) combined non-invasive PGT-A and PGT-A; (2) PGT-A; (3) non-invasive PGT-A. Basal characteristics, infertility history, ovarian reserve and embryo development of the three groups will be recorded. The samples will be detected ploidy by using next generation sequencing (NGS). Then, the investigators will choose embryo to transfer according to the embryo ploidy and follow the pregnancy outcomes after embryo transfer.

Outcome

  1. Concordance rate between non-invasive PGT-A and PGT-A

  2. The relationship between morphological grade and ploidy of non-invasive PGT-A

  3. IVF outcomes among non-invasive PGT-A, PGT-A and combined non-invasive PGT-A and PGT-A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Clinical Application of Non-invasive Preimplantation Genetic Testing for Aneuploidies
Actual Study Start Date :
Mar 24, 2021
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: combined non-invasive PGT-A & PGT-A

Infertility women who underwent both non-invasive PGT-A and PGT-A

Diagnostic Test: PGT-A
trophectoderm biopsy in blastocyst stage for euploidy testing using next generation sequencing platform

Diagnostic Test: non-invasive PGT-A
cell-free DNA collected from spent culture media for euploidy testing using next generation sequencing platform

Experimental: non-invasive PGT-A

Infertility women who underwent non-invasive PGT-A only

Diagnostic Test: non-invasive PGT-A
cell-free DNA collected from spent culture media for euploidy testing using next generation sequencing platform

Active Comparator: PGT-A

Infertility women who underwent PGT-A only

Diagnostic Test: PGT-A
trophectoderm biopsy in blastocyst stage for euploidy testing using next generation sequencing platform

Outcome Measures

Primary Outcome Measures

  1. Ongoing pregnancy rate [through study completion, an average of 1.5 year]

    continuous presence of a fetal heartbeat over 12 weeks of a pregnancy

Secondary Outcome Measures

  1. Clinical pregnancy rate [through study completion, an average of 1.5 year]

    the presence of a fetal heartbeat at 6-7 weeks of a pregnancy

  2. Miscarriage rate [through study completion, an average of 1.5 year]

    pregnancy loss before 24 weeks of gestation

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 44 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Infertile women who undergo IVF with PGT

  • BMI:18~30 kg/m2

Exclusion Criteria:
  • Primary ovarian insufficiency

  • Congenital uterine anomaly

  • Severe male infertility (azoospermia)

  • One of the couples with chromosome abnormality

  • Malignancy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kaohsiung Veterans General Hospital Kaohsiung Taiwan 81362

Sponsors and Collaborators

  • Kaohsiung Veterans General Hospital.
  • Sofiva Genomics Co., Ltd.

Investigators

  • Study Director: Kuan-Hao Tsui, Kaohsiung Veterans General Hospital.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Li-Te Lin, Attending doctor, Department of Obstetrics and Gynecology, Principal Investigator, Assistant professor, Kaohsiung Veterans General Hospital.
ClinicalTrials.gov Identifier:
NCT04856696
Other Study ID Numbers:
  • KSVGH20-CT12-16
First Posted:
Apr 23, 2021
Last Update Posted:
Mar 9, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Li-Te Lin, Attending doctor, Department of Obstetrics and Gynecology, Principal Investigator, Assistant professor, Kaohsiung Veterans General Hospital.

Study Results

No Results Posted as of Mar 9, 2022